Guizhou Yibai Pharmaceutical Co. Ltd. Class A

Guizhou Yibai Pharmaceutical Co. Ltd. Class A

SSSE:600594
3.04
CNY
-0.06
(-1.94%)
-0.50EPS
2.86BMarket Cap
Guizhou Yibai Pharmaceutical Co. Ltd. Class A
SSE:600594
(Shanghai Stock Exchange)

Recent

price

3.04

P/E

ratio

- -

div

yld

1.18%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
2.08
2.7
3.13
3.86
3.99
4.17
4.66
4.8
4.9
4.25
4.32
4.23
3.45
3.57
2.76
2.37
1.8
Revenue per Share
0.28
0.38
0.46
0.59
0.6
0.24
0.49
0.49
-1.1
0.16
0.28
0.31
-0.55
0.13
-0.4
-0.42
-0.5
Basic EPS, GAAP
0.09
0.19
0.11
0.42
0.43
0.36
0.06
0.35
-0.14
0.2
-0.04
0.61
0.03
0.31
-0.01
0.28
- -
Free Cash Flow per Basic Share
0.07
0.02
0.07
0.11
0.11
0.12
0.09
0.15
0.16
0.08
0.69
0.19
0.06
0.05
0.11
0.04
0.04
Dividend per Share
1.22
1.6
2.13
2.67
4.33
4.51
4.98
5.34
4.18
4.34
4.03
4.21
3.61
3.64
3.14
2.76
2.6
Book Value per Share
0.97
1.3
1.87
1.79
1.82
2.02
1.9
2.16
2.62
2.87
2.8
2.75
2.95
3.02
2.57
2.37
2.21
Tangible Book Value per Share
706
705
719
721
792
792
792
793
792
791
791
791
793
789
789
785
783
Basic Weighted Avg Shares
1,467
1,903
2,253
2,785
3,157
3,303
3,687
3,808
3,883
3,361
3,413
3,347
2,735
2,821
2,174
1,863
1,406
Sales/Revenue/Turnover
18.96
17.82
17.82
19.58
17.55
7.81
14.43
14.18
9.4
9.82
14.71
14.99
9.85
8.62
-10.09
-5.02
-11.35
Operating Margin (%)
43
48
47
46
82
86
113
139
179
153
141
150
181
201
193
171
- -
Depreciation Expense
196
265
333
429
478
189
385
387
-874
128
220
244
-438
103
-317
-330
-394
Net Income, GAAP
6.74
17.62
16.13
16.39
13.53
15.54
18.61
16.32
- -
43.06
31.94
25.64
- -
30.96
- -
- -
- -
Effective Tax Rate (%)
13.33
13.95
14.79
15.41
15.15
5.73
10.44
10.16
-22.5
3.81
6.44
7.28
-16.01
3.67
-14.59
-17.69
-28.04
Profit Margin (%)
392
613
1,079
694
952
878
605
925
1,137
1,650
748
641
868
1,140
801
539
445
Working Capital
21
1
51
21
251
251
377
755
515
776
94
328
372
418
330
102
96
LT Debt
870
1,138
1,546
1,932
3,442
3,586
4,240
4,641
3,762
3,560
3,291
3,391
3,007
3,018
2,606
2,271
2,116
Total Equity
17.99
19.32
19.24
19.05
13.43
3.66
7.2
6.38
- -
2.63
4.54
5.3
- -
2.34
- -
- -
- -
Return on Invested Capital (%)
20.14
21.71
21.26
21.34
15.55
5.2
8.15
7.17
- -
3.28
5.66
6.45
- -
3.22
- -
- -
- -
Return on Capital (%)
25.04
26.73
25.01
24.79
17.87
5.41
10.25
9.47
-23.18
3.8
6.63
7.47
-14.14
3.6
-11.81
-14.09
-17.5
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
563
539
577
LT Borrowings
150
150
86
LT Finance Leases
2
- -
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
792
792
784
Market Capitalization
3,136
2,352
2,855

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,443
1,345
1,264
Cash, Cash Equivalents & STI
490
430
403
Accounts Receivable, Net
130
129
128
Inventories
540
526
495
Total Current Liabilities
848
792
818
Payables & Accruals
- -
- -
- -
ST Debt
563
539
577
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.86%
-6.89%
-12.87%
Free Cash Flow
-352.38%
-682.72%
-2,446.64%
Net Income, GAAP
-106.04%
-159.05%
3.89%
Sales/Revenue/Turnover
-4.93%
-10.87%
-14.31%
Total Cash Common Dividend
62.33%
-22.43%
-66.98%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
573
596
546
460
2,174
2025
501
492
- -
416
1,863
2026
359
331
301
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.09
-0.05
-0.08
-0.19
-0.4
2025
-0.01
-0.01
- -
-0.31
-0.42
2026
-0.04
-0.06
-0.09
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.08
0.01
0.01
0.11
2025
0.01
0.01
- -
0.01
0.04
2026
0.01
0.01
0.01
- -
- -
Business
Guizhou Yibai Pharmaceutical Co., Ltd. (600594.SS) researches, develops, produces and sells pharmaceutical products principally in China; the company engages in pharmaceutical industry, medical services and big health industry segments. It manufactures chemical drugs, traditional Chinese medicines and biological drugs in forms including capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, pills and oral solutions targeting tumor, cerebrovascular, respiratory, rheumatism, digestive, pediatric, gynecological, anti-infection, anti-inflammatory and analgesic therapeutic areas; key products encompass injectable loboplatin (10mg and 50mg), Aidi injection, ginkgo damole injection, compound cantharide capsules, Ximaitong capsules, Rikitong blood drop pills, Dandeng Yiyang capsules, gynecologic hemostatic granules, gynecologic menstrual relief pills, Ishirokang tablets, Jinlian purifying effervescent tablets and Keke family cough products. Medical services involve operation and management of comprehensive hospitals, tumor specialty hospitals and tumor radiotherapy centers such as Mianyang Fulian Hospital, Liaoyang Zhongao Hospital and Deyang Cancer Hospital; big health offerings feature Miao medicine-based products including candy, plant beverages and ointments. Founded in 1995 and headquartered at No. 220-1 Baiyun Avenue, Yunyan District, Guiyang, Guizhou, the company listed on the Shanghai Stock Exchange in 2004 as Guizhou's first private listed enterprise and employs around 5,260 people with domestic market focus. In August 2025, it announced acquisition of Guizhou Yibai Traditional Chinese Medicine Formula Granule Pharmaceutical Co Ltd for CNY 11.15 million to expand traditional Chinese medicine capabilities; recent developments include resumption of production and sales for pediatric cough syrups following regulatory notices and integration of AI models like DeepSeek for administrative, medical and GMP compliance applications.